{"id":"NCT04410133","sponsor":"Blue Earth Diagnostics","briefTitle":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","officialTitle":"An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-26","primaryCompletion":"2023-06-05","completion":"2023-06-05","firstPosted":"2020-06-01","resultsPosted":"2025-08-28","lastUpdate":"2025-08-28"},"enrollment":151,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Brain Metastases"],"interventions":[{"type":"DRUG","name":"18F fluciclovine","otherNames":["Axumin"]}],"arms":[{"label":"Patients","type":"EXPERIMENTAL"}],"summary":"An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy","primaryOutcome":{"measure":"Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level","timeFrame":"MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.","effectByArm":[{"arm":"Reader 1 - Positive Percent Agreement (PPA)","deltaMin":23.8,"sd":null},{"arm":"Reader 2 - Positive Percent Agreement (PPA)","deltaMin":34.1,"sd":null},{"arm":"Reader 3 - Positive Percent Agreement (PPA)","deltaMin":36.6,"sd":null},{"arm":"Reader 1 - Negative Percent Agreement (NPA)","deltaMin":82.6,"sd":null},{"arm":"Reader 2 - Negative Percent Agreement (NPA)","deltaMin":70.9,"sd":null},{"arm":"Reader 3 - Negative Percent Agreement (NPA)","deltaMin":70.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["34081125"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":151},"commonTop":["Fatigue","Dizziness","Nausea","Infusion site bruising","Injection site reaction"]}}